The device, which contains flexible metal coils, is implanted into a woman’s fallopian tubes. After three months, tissue grows around the coils, blocking sperm from reaching eggs, thereby preventing pregnancy.
The warning reminds women to use an alternate form of birth control for the first three months after being implanted with the device and also lists various risks associated with Essure.
The FDA hopes the updated label will ensure women understand the benefits and risks associated with the permanent control device.
More articles on supply chain:
Supply chain tip of the week: Direct users to correct formularies
Novartis considers selling eye division
UPS workers vote to strike over health benefits: 5 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
